Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease

Inflammatory Bowel Diseases

Volumn 18, Issue 9, 2012, Pages 1608-1616

  Doherty, Glen A ^a,b   Miksad, Rebecca A ^a,b,c   Cheifetz, Adam S ^a,b   Moss, Alan C ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

cost effectiveness; Crohn's disease; decision analysis; prophylaxis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PLACEBO;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROHN DISEASE; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; MONTE CARLO METHOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; SENSITIVITY ANALYSIS;

6-MERCAPTOPURINE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; COST-BENEFIT ANALYSIS; CROHN DISEASE; DECISION TREES; HEALTH CARE COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MESALAMINE; MONTE CARLO METHOD; POSTOPERATIVE PERIOD; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 84865018679     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21904     Document Type: Article

References (37)

1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8: 244-250.
2. Bernell O, Lapidus A, Hellers G,. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. Br J Surg. 2000; 87: 1697-1701.
3. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut. 1984; 25: 665-672.
4. Borley NR, Mortensen NJ, Chaudry MA, et al. Recurrence after abdominal surgery for Crohn's disease: relationship to disease site and surgical procedure. Dis Colon Rectum. 2002; 45: 377-383.
5. Doherty G, Bennett G, Patil S, et al. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev. 2009; CD006873.
6. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of post-operative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol. 2009; 104: 2089-2096.
7. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54: 1121-1125.
8. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001; 96: 2929-2933.
9. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009; 136: 441-450.
10. Ollendorf DA, Lidsky L,. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. Am J Ther. 2006; 13: 502-506.
11. Lichtenstein GR, Hanauer SB, Sandborn WJ,. Management of Crohn's disease in adults. Am J Gastroenterol. 2009; 104: 465-483.
12. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. 2009. Washington, DC: National Academies Press.
13. Drummond M, Manca A, Sculpher M,. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care. 2005; 21: 165-171.
14. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276: 1339-1341.
15. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of post-operative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005; 128: 856-861.
16. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
17. Gregor JC, McDonald JWD, Klar N, et al. An evaluation of utility measurements in Crohn's disease. Inflamm Bowel Dis. 1997; 3: 265-276.
18. Gibson PR, Weston AR, Shann A, et al. Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease. J Gastroenterol Hepatol. 2007; 22: 1306-1312.
19. Chung JB, Armstrong K, Schwartz JS, et al. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum. 2000; 43: 1841-1848.
20. Kaplan GG, Hur C, Korzenik J, et al. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007; 26: 1509-1520.
21. Yen EF, Kane SV, Ladabaum U,. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. Am J Gastroenterol. 2008; 103: 3094-3105.
22. Red Book: Pharmacy's Fundamental Reference. New York: Thomson Reuters; 2009.
23. Wu EQ, Mulani PM, Yu AP, et al. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective. Value Health. 2008; 11: 820-829.
24. CPT Code / Relative Value Search. https://catalog.ama-assn.org/Catalog/ cpt/cpt-search-result.jsp?requestid=2745105. 2010.
25. Sussman DA, Kubiliun N, Chao J, et al. Comparison of medical costs among patients using adalimumab or infliximab: a retrospective study (COMPAIRS). Am J Gastroenterol. 2010; 105 (Suppl 1): S436-S437.
26. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008; 135: 1907-1913.
27. Malone DC, Waters HC, Van Den BJ, et al. A claims-based Markov model for Crohn's disease. Aliment Pharmacol Ther. 2010; 32: 448-458.
28. Jones DW, Finlayson SR,. Trends in surgery for Crohn's disease in the era of infliximab. Ann Surg. 2010; 252: 307-312.
29. Regueiro M, Schraut W, Baidoo L, et al. Two year post-operative follow-up of patients enrolled in the randomised controlled trial of infliximab to prevent recurrent Crohn's disease. Gastroenterology. 2009; 136: A522.-
30. Lemann M,. Review article: can post-operative recurrence in Crohn's disease be prevented? Aliment Pharmacol Ther. 2006; 24 (Suppl 3): 22-28.
31. Avidan B, Sakhnini E, Lahat A, et al. Risk factors regarding the need for a second operation in patients with Crohn's disease. Digestion. 2005; 72: 248-253.
32. Yamamoto T,. Factors affecting recurrence after surgery for Crohn's disease. World J Gastroenterol. 2005; 11: 3971-3979.
33. Swoger JM, Regueiro M,. Postoperative Crohn's disease: how can we prevent it? Expert Rev Clin Immunol. 2010; 6: 501-504.
34. Bordeianou L, Stein SL, Ho VP, et al. Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease? Surgery. 2011; 149: 72-78.
35. Kennedy ED, To T, Steinhart AH, et al. Do patients consider postoperative maintenance therapy for Crohn's disease worthwhile? Inflamm Bowel Dis. 2008; 14: 224-235.
36. Kennedy ED, Detsky AS, Llewellyn-Thomas HA, et al. Can the standard gamble be used to determine utilities for uncertain health states? An example using postoperative maintenance therapy in Crohn's disease. Med Decis Making. 2000; 20: 72-78.
37. Kane SV, Loftus EV, Sandborn WJ, et al. Limited clinical utility of a self-administered tool for predicting medication adherence behavior in IBD. Gastroenterology. 2011; 140.